RCT: Sintilimab plus a bevacizumab biosimilar versus sorafenib in unresectable hepatocellular carcinoma.

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Sintilimab Plus Bevacizumab Biosimilar vs Sorafenib in Unresectable or Metastatic HBV-Associated Hepatocellular Carcinoma – The ASCO Post

Commentary on Twitter

In a phase III trial involving 571 pts with unresectable HCC, the anti-PD-1 mAb sintilimab + the bevacizumab biosimilar IBI305 improved PFS (median 4.6 vs 2.8 months with sorafenib; HR 0.56, P <0.0001) & OS (median NR vs 10.4 months; HR 0.57, P <0.0001), https://t.co/UF43FGdMMy

— NatureRevClinOncol (@NatRevClinOncol) June 22, 2021